Nalaganje...
Trastuzumab: updated mechanisms of action and resistance in breast cancer
HER2-postitive breast cancer has the second-poorest prognosis among breast cancer subtypes. One of the most effective targeted therapies for patients with HER2-positive breast cancer is trastuzumab-based. However, primary or acquired resistance to trastuzumab has been a major obstacle in the clinica...
Shranjeno v:
Main Authors: | , |
---|---|
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
Frontiers Media S.A.
2012-06-01
|
Serija: | Frontiers in Oncology |
Teme: | |
Online dostop: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00062/full |
Oznake: |
Označite
Brez oznak, prvi označite!
|